glp 1 new drug GLP-1 Agonists: A Comprehensive Overview Indications for GLP-1/GIP RA Summary
Description
Signs and symptoms may vary depending on the anatomical location

doi: 10.1530/acta.0.0440139
:max_bytes(150000):strip_icc()/VWH-GettyImages-2275860768-a6f6e63304e048d0a829844c1dacbd8d.jpg)
An exploratory signal suggested a potential lower risk of heart failure hospitalization with semaglutide compared to dapagliflozin

Abstract Cardiovascular outcome trials (CVOTs) in people living with type 2 diabetes mellitus and obesity have confirmed the cardiovascular benefits of glucagon-like peptide 1 receptor agonists (GLP-1RAs), including reduced cardiovascular mortality, lower rates of myocardial infarction, and lower rates of stroke

These drugs aid in weight loss by reducing hunger, slowing the digestion of food, and increasing metabolism

Diabetologia 67 , 483493 (2024)
